Literature DB >> 16103621

Hepatitis a in Lebanon: a changing epidemiological pattern.

Robert G Sacy1, Mirna Haddad, Ghassan Baasiri, Adlette Khoriati, Bernard J Gerbaka, Remon Abu-Elyazeed.   

Abstract

In this multicenter study in Lebanon, hepatitis A virus (HAV) seroprevalence rates were surveyed by age, gender, and socioeconomic factors. Blood samples collected from 606 subjects aged 1 to 30 years were analyzed for anti-HAV IgG. Age was the most important factor influencing HAV seroprevalence. HAV seroprevalence rates in the current study were about 78% in the > or = 21 years age group, 28% in the 6-10 years age group, and 11% in the 1-5 years age group as compared with 97.7% in adults, 85% in children aged 6-12 years, and 40% in children aged 1 to 5 years in previous studies, demonstrating a shift in HAV seroprevalence from the younger to the higher age groups. In light of the severity of the disease in adults and availability of safe and effective vaccines against HAV infection, introduction of HAV vaccination into the national immunization schedule of Lebanon should be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103621

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  Community-based cross-sectional seroprevalence study of hepatitis A in Bangladesh.

Authors:  Samir K Saha; Setarunnahar Saha; Salim Shakur; Mohammed Hanif; Md Ahsan Habib; Sanjoy K Datta; Hans L Bock
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

2.  Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: Implications for hepatitis A vaccination.

Authors:  Eduardo Lazcano-Ponce; Carlos Conde-Gonzalez; Rosalba Rojas; Rodrigo DeAntonio; Luis Romano-Mazzotti; Yolanda Cervantes; Eduardo Ortega-Barria
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

3.  Hepatitis A virus infection: Is it an important hazard to public health?: hazards of HAV for public health.

Authors:  Mehdi Saberifiroozi
Journal:  Hepat Mon       Date:  2011-04       Impact factor: 0.660

4.  Hepatitis A vaccination in developing countries: Is Syria next?

Authors:  Ghaith Habboub; Shadi M Alhalabi; Ghaith Mousabasha; Zaid Al-Faham
Journal:  Avicenna J Med       Date:  2012-07

5.  Seroprevalence of hepatitis A virus antibody in a population aged 0-30 years in Shanghai, China: implications for hepatitis A immunization.

Authors:  Y Zhu; Z Yuan; Q Zhao; G Chen; B Xu
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

6.  Age-specific seroprevalence of anti-hepatitis a antibody among 1-30 years old population of savadkuh, mazandaran, iran with literature review.

Authors:  Mohammed Jafar Saffar; Omid Abedian; Abolghasem Ajami; Farshideh Abedian; Araz Mohammad Mirabi; Ali-Reza Khalilian; Hana Saffar
Journal:  Hepat Mon       Date:  2012-05-30       Impact factor: 0.660

7.  Evidence of Circulation of Several HAV Genetic Variants and Emergence of Potential Antigenic Variants in an Endemo-Epidemic Country before Vaccine Introduction.

Authors:  Kaouther Ayouni; Anissa Chouikha; Oussema Khamessi; Henda Touzi; Walid Hammemi; Henda Triki
Journal:  Viruses       Date:  2021-06-03       Impact factor: 5.048

8.  Seroprevalence of fecal-oral transmitted hepatitis A and E virus antibodies in Burkina Faso.

Authors:  Kuan Abdoulaye Traoré; Hortense Rouamba; Yacouba Nébié; Mahamadou Sanou; Alfred S Traoré; Nicolas Barro; Pierre Roques
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

9.  Hepatitis a virus: is vaccination necessary in middle East?

Authors:  Mehdi Saberifiroozi
Journal:  Middle East J Dig Dis       Date:  2013-07

10.  Hepatitis A among refugees, asylum seekers and migrants living in hosting facilities, Greece, April to December 2016.

Authors:  Kassiani Mellou; Anthi Chrisostomou; Theologia Sideroglou; Theano Georgakopoulou; Maria Kyritsi; Christos Hadjichristodoulou; Sotirios Tsiodras
Journal:  Euro Surveill       Date:  2017-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.